Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer

Project Information

OVACell

Grant agreement ID: 101145335

DOI

10.3030/101145335

Project closed

EC signature date 6 February 2024

Start date 1 March 2024

End date 31 August 2025

Funded under

• The European Innovation Council (EIC)

Total cost

€ 3 650 067,50

EU contribution

€ 2 499 999,00

Coordinated by

ERVIMMUNE
France

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Websites, patent fillings, videos etc. (1)

Press releases

Press release on the obtention of the EIC Accelerator

Publications

Other (1)

HERV-derived epitopes represent new targets for T-cell based immunotherapies in ovarian cancer

Author(s): Paola Bonaventura, Olivier Tabone, Yann Estornes, Audrey Page, Virginie Mutez, Marie Delles, Sarah Moran, Clarisse Dubois, Marjorie Lacourrege, Dina Tawfik, Ema Etchegaray, Adrian Valente, Rasha E. Boulos, Gabriel Jimenez Dominguez, Nicolas Chuvin, Nicolas Gadot, Qing Wang, Jenny Valladeau-Guilemond, Stéphane Depil
Published in: 2024
Publisher: biorxiv